Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
National Hematology Research Center, Moscow, Russian Federation
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Children's hospital of Fudan university, Shanghai, Shanghai, China
Shanghai Children's Hospital, Shanghai, China
M D Anderson Cancer Center, Houston, Texas, United States
NYU Langone Health, New York, New York, United States
Columbia University, New York, New York, United States
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.